Windtree Therapeutics, Inc. - WINT STOCK NEWS

Windtree Therapeutics, Inc. (WINT) is advancing its drug candidate, istaroxime, targeting cardiogenic shock. The company announced acceptance of their abstract on istaroxime's safety and efficacy for presentation at the Technology and Heart Failure Therapeutics Conference from March 20-22, 2023. Data from the SEISMiC Phase 2 study showed that istaroxime significantly improved systolic blood pressure (SBP) over six hours and maintained this improvement through the 24-hour mark. No increase in cardiac arrhythmias was observed, indicating a potentially valuable therapy for heart failure. The analysis will further detail dose-specific data at the conference.

Windtree Therapeutics (WINT) has announced the issuance of U.S. Patent No. 11,583,540, extending patent protection for its investigational drug, istaroxime, until late 2039. Istaroxime is being studied for acute heart failure and cardiogenic shock, showcasing a dual mechanism that enhances both heart contraction and relaxation. The new patent allows for longer infusion durations, improving treatment outcomes. The CEO emphasized the drug's unique benefits compared to existing treatments. This strategic move strengthens Windtree's intellectual property portfolio as it advances its late-stage cardiovascular interventions.

Windtree Therapeutics, Inc. (NASDAQ: WINT) announced a 1-for-50 reverse stock split effective February 24, 2023. The decision, approved by stockholders on February 7, 2023, aims to increase the stock price to meet the $1 minimum bid requirement for The Nasdaq Capital Market. As a result, approximately 44.5 million shares will reduce to 0.9 million shares, with proportional adjustments to stock options and warrants. The reverse split will not impact stockholders' percentage ownership, and fractional shares will be rounded up. Continental Stock Transfer & Trust Company acts as the transfer agent for the split.

Windtree Therapeutics, Inc. (NASDAQ: WINT) announced on January 20, 2023, a warrant inducement offer to raise approximately $1.0 million by exercising warrants for 4,808,595 shares of common stock. The exercise price of certain previously issued warrants was reduced to $0.20 per share from prices as high as $12.09. In conjunction, new warrants to purchase 9,617,190 shares at $0.2152 will be issued. Completion of this transaction is expected to bolster the company’s capital before fees. The new warrants will be exercisable in six months and will expire in five years. The offerings are conducted through a private placement to accredited investors, exempt from registration requirements.

Windtree Therapeutics (WINT) announced an extension from Nasdaq, granting an additional 180 days to comply with the $1.00 minimum bid price requirement. This period extends until May 29, 2023. If WINT’s shares close at or above $1.00 for 10 consecutive days, it will regain compliance. The company may also opt for a reverse stock split to meet this requirement. Failure to comply by the deadline may lead to delisting, but it can appeal such a decision. Currently, the notification does not affect the trading status of WINT shares on Nasdaq.

Windtree Therapeutics (NasdaqCM: WINT) reported its Q3 2022 financial results, reflecting an operating loss of $4.7 million, a significant reduction from $8.1 million in Q3 2021. R&D expenses fell to $1.5 million, down from $4.7 million, focusing resources on istaroxime development after a successful SEISMiC study. The company announced a global license agreement with Lee's Pharmaceutical, potentially yielding up to $78.9 million. Cash and equivalents were $8.4 million, expected to fund operations into Q2 2023. Positive results in istaroxime studies were published, and a new patent was allowed by the USPTO.

Windtree Therapeutics (NasdaqCM: WINT) announced a significant milestone with the Notice of Allowance for a new patent concerning istaroxime administration, enhancing its patent estate until late 2039. This investigational drug targets acute heart failure and cardiogenic shock, demonstrating improvements in cardiac function and blood pressure without adverse cardiac events.

The new patent focuses on longer infusion durations for istaroxime, building upon existing patents and reinforcing the company’s commitment to innovation in cardiovascular therapies.

Windtree Therapeutics (WINT) announced positive results from its Phase 2 istaroxime study for early cardiogenic shock, published in the European Journal of Heart Failure. The SEISMiC study showed that istaroxime significantly improved systolic blood pressure and cardiac function without worsening renal function. These findings support istaroxime's potential as a treatment for cardiogenic shock, a condition with high mortality rates and limited effective therapies. Windtree plans to optimize dosing and is set to discuss the next Phase 3 program with the FDA.

Windtree Therapeutics (WINT) has announced a late-breaking abstract presentation for its Phase 2 clinical study of istaroxime, targeting early cardiogenic shock, at the Heart Failure Society of America's Annual Meeting on October 2. The SEISMiC study demonstrated significant improvement in systolic blood pressure within the first 6 hours and maintained benefits through 24 hours. Patients showed enhanced stroke volume and cardiac output without increased heart rate, with no worsening of renal function. Cardiogenic shock represents a market valued at $1.25 billion, highlighting the urgent need for innovative treatments.